OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction ...
16 February 2021 - 11:30PM
Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”), a subsidiary
of OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the
publication of a peer-reviewed study introducing best practice
techniques for prediction of antibiotic susceptibility testing
(AST) results from whole-genome sequencing (WGS) data.
The work led by Ares Genetics and performed in
collaboration with Prof. Thomas Rattei from the Division of
Computational Systems Biology at the University of Vienna
critically assessed different machine learning (ML) techniques for
whole genome sequencing (WGS)-based AST on several thousand genome
assemblies across more than 50 species/compound combinations
collated from public databases. The publication describes the
combination of different machine learning architectures for robust
and accurate WGS-based AST.
The study addresses two out of five actions
stipulated by the FDA in the recently issued Artificial
Intelligence/Machine Learning (AI/ML)-Based Software as a Medical
Device (SaMD) Action Plan. It aims at advancing good machine
learning practices (GMLP) for WGS-based AST by describing best
practice techniques for training and evaluation of predictive
models, as well as introducing an optimized model architecture to
reduce bias and promote robustness.
Dr. Arne Materna, CEO of Ares Genetics,
commented, “The present study adds to Ares Genetics’ publication
record validating our approach to becoming a globally recognized
leader in the development of AI-powered next generation sequencing
or NGS-based solutions for infectious disease testing. Addressing
the U.S. FDA action plan by developing good machine learning
practice and robust algorithms will be key to moving our AI-powered
solutions into clinical practice. Applying the proposed best
practice techniques to our unique and curated ARESdb allowed us to
further improve predictive performance of WGS-based AST even beyond
the performance shown in our seminal multi-center evaluation study
demonstrating feasibility of WGS-based AST for a broad selection of
pathogen-drug combinations. In this context, we are currently also
working with several leading clinical centers in the United States
to further demonstrate the potential of accurate WGS-based AST in
independent validation studies.”
Oliver Schacht, President & CEO of OpGen
added, “The Ares Technology platform is an integral part of OpGen’s
precision medicine offering and complements our commercial
FDA-approved Unyvero platform as well as our Acuitas AMR Gene Panel
for isolates for which we anticipate an upcoming FDA clearance
decision. Following the successful integration of Ares Genetics
into OpGen globally, we are focused on executing on our strategy to
establish ourselves as industry leaders in the artificial
intelligence and bioinformatics space.”
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements by
OpGen
This press release includes statements regarding
the recently published benchmarking study on AI-powered prediction
of antibiotic susceptibility. These statements and other statements
regarding OpGen’s Unyvero products, their commercialization and
launch, future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control, and which
may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those
described include, but are not limited to, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product and services
offerings, the rate of adoption of our products and services by
hospitals and other healthcare providers, the fact that we may not
effectively use proceeds from recent financings, including our
November 2020 private placement, the realization of expected
benefits of our business combination transaction with Curetis GmbH,
the success of our commercialization efforts, the impact of
COVID-19 on the Company’s operations, financial results, and
commercialization efforts as well as on capital markets and general
economic conditions, the effect on our business of existing and new
regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen Contact:Oliver
SchachtCEOInvestorRelations@opgen.com
Press Contact:Matthew
BretziusFischTank Marketing and PRmatt@fischtankpr.com
Investor Contact:Megan
PaulEdison Groupmpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024